News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Egalet Initiates Bioequivalence Studies For Abuse-Deterrent Morphine Egalet-001


3/25/2014 9:19:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WAYNE, Penn., March 25, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the initiation of the bioequivalence (BE) program for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. These studies are intended to establish bioequivalence of Egalet-001 to MS ContinĀ® (morphine sulfate controlled-release) ("MS Contin").

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Egalet
 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES